文献速递静脉血栓栓塞

静脉血栓栓塞症作为恶性肿瘤的首发征象

Venous thromboembolism as the first sign of malignancy.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2022-07-22

基于美国全国再入院数据库的1年回顾性分析纳入116048例以深静脉血栓或肺栓塞为首发诊断的患者,排除已知恶性肿瘤者。6个月内新诊断恶性肿瘤发生率为2.4%(2354例),最常见的为胃肠道肿瘤(29.2%)。年龄≥65岁、女性、下腔静脉血栓、上肢血栓及Charlson合并症指数≥5分是预测因素,静脉血栓栓塞症恶性肿瘤评分 cut-off 为3分(敏感性86%,特异性89%)。

要点

  • 静脉血栓栓塞症患者6个月内新发恶性肿瘤发生率为2.4%。
  • 最常见的新发恶性肿瘤为胃肠道肿瘤,占29.2%。
  • 静脉血栓栓塞症恶性肿瘤评分≥3分预测6个月内新发恶性肿瘤的敏感性86%、特异性89%。

核心结论

  • 静脉血栓栓塞症可能是潜在恶性肿瘤的风险指标。
  • 基于多种人口学或合并症预测因素的风险分层评分经验证后,可能为早期诊断隐匿性恶性肿瘤提供机会。

研究设计与样本

  • 美国全国再入院数据库的1年回顾性分析,纳入年龄18岁及以上、以深静脉血栓或肺栓塞为首发诊断的患者,排除已知恶性肿瘤者。
  • 共识别116048例静脉血栓栓塞症患者(深静脉血栓49.8%,肺栓塞41.7%,深静脉血栓合并肺栓塞8.6%),其中16%(n=18294)患有恶性肿瘤。
  • 其余97754例患者中,31%在6个月内再入院。

主要发现

  • 6个月内新诊断恶性肿瘤的发生率为2.4%(n=2354)。
  • 最常见的新发恶性肿瘤为胃肠道来源,占29.2%。
  • 恶性肿瘤的人口学和诊断预测因素包括年龄65岁及以上、女性、下腔静脉血栓、上肢血栓及Charlson合并症指数评分5分或以上。
  • 受试者工作特征曲线分析发现静脉血栓栓塞症恶性肿瘤评分 cut-off 为3分(敏感性86%,特异性89%)可预测6个月内新发现恶性肿瘤风险增加。

关键数值与推荐

  • 静脉血栓栓塞症恶性肿瘤评分 cut-off 为3分时,预测6个月内新发恶性肿瘤的敏感性为86%,特异性为89%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) is commonly associated with hypercoagulability in patients with cancer; however, there have been few investigations of VTE as the first sign of malignancy and even fewer performed in the United States. The aim of our study was to evaluate the incidence and predictors of unrecognized malignancy in patients presenting with VTE. METHODS: We performed a 1-year retrospective analysis of the Nationwide Readmission Database, including patients aged 18 years or older, presenting with a primary diagnosis of deep vein thrombosis (DVT) or a pulmonary embolism (PE). Patients known to have preexisting malignant diseases were excluded. Outcomes included the rate of newly diagnosed malignancy within 6 months from the discovery of VTE and demographic or associated illness predictors for the diagnosis of malignancy. A regression analysis was performed, based on which a VTE malignancy score was developed. RESULTS: A total of 116,048 patients were identified with VTE (49.8% DVT, 41.7% PE, 8.6% DVT and PE), 16% (n = 18,294) with malignancy. Of the remaining 97,754 patients, 31% were readmitted within 6 months. The incidence of newly diagnosed malignancy within 6 months was 2.4% (n = 2354). The most common malignancies were gastrointestinal in origin (29.2%). Demographic and diagnostic predictors for malignancy included age 65 years or older, female sex, inferior vena cava (IVC) thrombus, upper extremity thrombus, and a Charlson Comorbidity Index score of 5 or more. Receiver operating characteristic curve analysis found a cutoff VTE Malignancy score of 3 (sensitivity, 86%; specificity, 89%) to be predictive of an increased risk of a newly discovered malignancy within 6 months. CONCLUSIONS: VTE can be a risk indicator of underlying malignancy. Validation of a patient risk stratification score using multiple demographic or comorbid predictors for VTE on index admission may offer an opportunity for earlier diagnosis of occult malignancy.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Pandit V, Kempe K, Hanna K, et al. Venous thromboembolism as the first sign of malignancy. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 35872141. doi:10.1016/j.jvsv.2022.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。